DE60004017D1 - Heterocyclische benzolsulfonamidderivate als bradykinin antagonisten - Google Patents

Heterocyclische benzolsulfonamidderivate als bradykinin antagonisten

Info

Publication number
DE60004017D1
DE60004017D1 DE60004017T DE60004017T DE60004017D1 DE 60004017 D1 DE60004017 D1 DE 60004017D1 DE 60004017 T DE60004017 T DE 60004017T DE 60004017 T DE60004017 T DE 60004017T DE 60004017 D1 DE60004017 D1 DE 60004017D1
Authority
DE
Germany
Prior art keywords
bradykinin antagonists
benzene sulphonamide
sulphonamide derivatives
heterocyclic benzene
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60004017T
Other languages
English (en)
Other versions
DE60004017T2 (de
Inventor
Pierre Dodey
Martine Barth
Michel Bondoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fournier Industrie et Sante SAS
Original Assignee
Fournier Industrie et Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Industrie et Sante SAS filed Critical Fournier Industrie et Sante SAS
Publication of DE60004017D1 publication Critical patent/DE60004017D1/de
Application granted granted Critical
Publication of DE60004017T2 publication Critical patent/DE60004017T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
DE60004017T 1999-02-26 2000-02-17 Heterocyclische benzolsulfonamidderivate als bradykinin antagonisten Expired - Lifetime DE60004017T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9902412A FR2790260B1 (fr) 1999-02-26 1999-02-26 Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
FR9902412 1999-02-26
PCT/FR2000/000396 WO2000050418A1 (fr) 1999-02-26 2000-02-17 Composes heterocycliques de benzenesulfonamide en tant qu'antagonistes de la bradykinine

Publications (2)

Publication Number Publication Date
DE60004017D1 true DE60004017D1 (de) 2003-08-28
DE60004017T2 DE60004017T2 (de) 2004-07-01

Family

ID=9542576

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60004017T Expired - Lifetime DE60004017T2 (de) 1999-02-26 2000-02-17 Heterocyclische benzolsulfonamidderivate als bradykinin antagonisten

Country Status (31)

Country Link
US (1) US6479515B1 (de)
EP (1) EP1155013B1 (de)
JP (1) JP4564666B2 (de)
KR (1) KR20010102057A (de)
CN (1) CN1340050A (de)
AR (1) AR022754A1 (de)
AT (1) ATE245640T1 (de)
AU (1) AU2809600A (de)
BG (1) BG105840A (de)
BR (1) BR0008221A (de)
CA (1) CA2371853C (de)
CZ (1) CZ303169B6 (de)
DE (1) DE60004017T2 (de)
DK (1) DK1155013T3 (de)
EE (1) EE04839B1 (de)
ES (1) ES2202059T3 (de)
FR (1) FR2790260B1 (de)
HK (1) HK1041267A1 (de)
HR (1) HRP20010619A2 (de)
HU (1) HUP0200281A3 (de)
ID (1) ID29914A (de)
IL (1) IL144720A0 (de)
MX (1) MXPA01008672A (de)
NO (1) NO20014048L (de)
NZ (1) NZ513732A (de)
PL (1) PL199209B1 (de)
PT (1) PT1155013E (de)
SK (1) SK286710B6 (de)
TN (1) TNSN00031A1 (de)
WO (1) WO2000050418A1 (de)
ZA (1) ZA200106250B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
WO2004056319A2 (en) * 2002-12-19 2004-07-08 Elan Pharmaceuticals Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
CA2522084A1 (en) * 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
CA2524274A1 (en) * 2003-05-02 2004-11-18 Elan Pharmaceuticals, Inc. 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
JP2006526015A (ja) 2003-05-02 2006-11-16 エラン ファーマシューティカルズ，インコーポレイテッド 炎症疾患治療のためのブラジキニンｂ１受容体アンタゴニストとしての４−ブロモ−５−（２−クロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸アミド誘導体および関連化合物
EP1635821B1 (de) * 2003-05-02 2009-07-08 Elan Pharmaceuticals, Inc. 4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3-carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen
EP2066659B1 (de) * 2006-09-29 2013-08-28 Grünenthal GmbH Substituierte sulfonamid-derivate
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
AU2013226013B2 (en) * 2012-02-29 2016-08-11 Baruch S. Blumberg Institute Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation and Their Method of Use
UY37981A (es) 2017-11-24 2019-06-28 Pharvaris B V Novedosos antagonistas del receptor b2 de bradiquinina
UY38707A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Nuevos antagonistas cíclicos del receptor b2 de bradiquinina
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物
WO2023180575A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3617183A1 (de) 1985-11-16 1987-05-27 Bayer Ag Substituierte benzylether
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5610140A (en) 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
EP0586613A4 (en) 1991-04-01 1994-08-24 Cortech Inc Bradykinin antagonists
TW258739B (de) 1992-04-04 1995-10-01 Hoechst Ag
US5610142A (en) 1992-10-08 1997-03-11 Scios Inc. Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids
AU686115B2 (en) 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
US5510380A (en) 1993-02-19 1996-04-23 Sterling Winthrop, Inc. Nonpeptide bradykinin antagonists
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
CN1168667A (zh) 1994-10-27 1997-12-24 藤沢药品工业株式会社 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
FR2735128B1 (fr) 1995-06-07 1997-07-25 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, leur procede de preparation et utilisation en therapeutique.
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
US5834431A (en) 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
US5849863A (en) 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
GB9519077D0 (en) 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
AUPN952696A0 (en) * 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2756562B1 (fr) * 1996-12-04 1999-01-08 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
FR2765222B1 (fr) 1997-06-27 1999-12-31 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique

Also Published As

Publication number Publication date
SK11922001A3 (sk) 2001-12-03
PL350234A1 (en) 2002-11-18
JP2002537392A (ja) 2002-11-05
HUP0200281A3 (en) 2003-05-28
NZ513732A (en) 2001-09-28
US6479515B1 (en) 2002-11-12
EE04839B1 (et) 2007-06-15
EE200100444A (et) 2002-12-16
FR2790260A1 (fr) 2000-09-01
BG105840A (en) 2002-04-30
CA2371853A1 (en) 2000-08-31
HK1041267A1 (zh) 2002-07-05
HUP0200281A2 (en) 2002-06-29
JP4564666B2 (ja) 2010-10-20
IL144720A0 (en) 2002-06-30
AU2809600A (en) 2000-09-14
ATE245640T1 (de) 2003-08-15
PL199209B1 (pl) 2008-08-29
NO20014048D0 (no) 2001-08-20
HRP20010619A2 (en) 2002-08-31
KR20010102057A (ko) 2001-11-15
CA2371853C (en) 2009-09-29
SK286710B6 (sk) 2009-03-05
CZ20013067A3 (cs) 2001-11-14
ZA200106250B (en) 2002-07-30
CN1340050A (zh) 2002-03-13
WO2000050418A1 (fr) 2000-08-31
ID29914A (id) 2001-10-25
DK1155013T3 (da) 2003-11-17
WO2000050418A9 (fr) 2001-02-22
EP1155013B1 (de) 2003-07-23
TNSN00031A1 (fr) 2005-11-10
PT1155013E (pt) 2003-12-31
AR022754A1 (es) 2002-09-04
MXPA01008672A (es) 2003-06-24
DE60004017T2 (de) 2004-07-01
NO20014048L (no) 2001-08-20
ES2202059T3 (es) 2004-04-01
FR2790260B1 (fr) 2001-05-04
CZ303169B6 (cs) 2012-05-09
BR0008221A (pt) 2001-11-20
EP1155013A1 (de) 2001-11-21

Similar Documents

Publication Publication Date Title
DE60032601D1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
NO20016116D0 (no) Substituerte heterocykliske fuserte gamma-karboliner
ATE299865T1 (de) Piperazinderivate verwendbar als ccr5 antagonisten
ATE259363T1 (de) Piperazinderivate als 5-ht1b antagonisten
ATE330954T1 (de) Quinazolin-derivate als vegf-hemmer
DE60004017D1 (de) Heterocyclische benzolsulfonamidderivate als bradykinin antagonisten
IS6366A (is) Heterósýklísk setin pýrazólón
NO20013559D0 (no) Aromatiske heterocykliske forbindelser som anti- inflammatoriske midler
ATE299142T1 (de) Phenylpiperazin-derivate als inhibitoren der serotonin-wiederaufnahme
DE60113563D1 (de) Substituierte 2-phenylaminoimidazolin-phenyl-ketonderivate als ip-antagonisten
DE60114852D1 (de) Chinazolin-derivate als alpha-1 adrenerge antagonisten
NO20015779D0 (no) Bradykinin-reseptorantagonister
ATE254621T1 (de) Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
ATE286018T1 (de) Biphenylderivate als neurokinin-1 antagonisten
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
IS6434A (is) Nýjar indól afleiður
ATE264301T1 (de) Muscarin-antagonisten
ATE506357T1 (de) Heterocyclische aminoalkylpyridinderivate als psychopharmaka
DE60012953D1 (de) 3-amino-2-phenylpiperidinderivate als substanz p antagonisten
ATE367379T1 (de) Quinolin-derivate als antientzündungsmittel
ATE252554T1 (de) Cinnamoylaminoalkyl-substituierte benzenesulfonamid-derivate
SI1155013T1 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition